Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 4, 2009, Pages 452-458

  Avidan, Neumann U ^a,b,c   Goldstein, Deborah ^d   Rozenberg, Lynn ^a   McLaughlin, Mary ^b   Ferenci, Peter ^e   Masur, Henry ^f   Buti, Maria ^g   Fauci, Anthony S ^b   Polis, Michael A ^b   Kottilil, Shyam ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HCV; HIV; Sustained viral response; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MALE; MIXED INFECTION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; KINETICS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 74049088591     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181be7249     Document Type: Article

References (24)

1. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
2. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (Baltimore, Md). 1999;30:1054-1058. (Pubitemid 29458296)
3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
4. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS (London, England). 2003;17:1023-1028. (Pubitemid 36549714)
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
7. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
8. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
9. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282: 103-107.
10. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother. 2004;53:15-18.
11. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis. 2003;188:1498-1507.
12. Talal AH, Shata MT, Markatou M, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr. 2004;35:103-113.
13. Sherman KE, Shire NJ, Rouster SD, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroen-terology. 2005;128:313-327.
14. Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology. 2006;43:943-953.
15. Wu L, Kottilil S, Lempicki R, et al. Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR). AIDS Res Hum Retroviruses. 2006;22:1091-1098.
16. Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology (Baltimore, Md). 2003;37:1343-1350.
17. Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepatitis. 2003;10:271-276.
18. Perelson AS, Herrmann E, Micol F, et al. New kinetic models for the hepatitis C virus. Hepatology (Baltimore, Md). 2005;42:749-754.
19. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23:585-591. (Pubitemid 26304511)
20. Soriano V, Bravo R, Garcia-Samaniego J, et al. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group. J Infect. 1997;35:225-230.
21. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection. 1998;26:16-19.
22. Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia. 2000;6:677-681.
23. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000;182: 28-35.
24. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008;47:36-49.